Saturday, June 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

‘Gamechanging’ weight loss drug to be made available on NHS

Thousands of people with obesity in England will be able to get a new weight loss drug on the NHS after a watchdog approved its use.

Patients on the weekly injections have seen their weight fall by an average of 12% after one year, the National Institute for Health and Care Excellence (Nice) said.

It has issued draft guidance recommending semaglutide, also known as Wegovy, for adults with at least one weight-related condition, such as obstructive sleep apnoea or heart disease, and a body mass index (BMI) of at least 35.

In exceptional cases, some people with a BMI of 30 or more may also be able to access the drug, which is self-administered using a pen injector.

Source: The Guardian

https://www.theguardian.com/society/2022/feb/08/gamechanging-weight-loss-drug-made-available-nhs-semaglutide-obesity

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!